NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

ALK is involved in the onset of several tumors. Crizotinib (Xalkori(TM)), a potent ALK inhibitor, represents the current front-line treatment for ALK+ NSCLC and shows great clinical efficacy. However, resistant disease often develops after initial response. ASP3026 is a novel second-generation ALK i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Mologni, Luca, Ceccon, Monica, Pirola, Alessandra, Chiriano, Gianpaolo, Piazza, Rocco, Scapozza, Leonardo, Gambacorti-Passerini, Carlo
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467397/
https://ncbi.nlm.nih.gov/pubmed/25749034
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires